IPO Year:
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/2/2025 | $12.00 | Buy | TD Cowen |
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
TD Cowen initiated coverage of Grace Therapeutics with a rating of Buy and set a new price target of $12.00
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Grace Therapeutics, Inc. (0001444192) (Issuer)
4 - Grace Therapeutics, Inc. (0001444192) (Issuer)
4 - Grace Therapeutics, Inc. (0001444192) (Issuer)
4 - Grace Therapeutics, Inc. (0001444192) (Issuer)
4 - Grace Therapeutics, Inc. (0001444192) (Issuer)
4 - Grace Therapeutics, Inc. (0001444192) (Issuer)
4 - Grace Therapeutics, Inc. (0001444192) (Issuer)
4 - Grace Therapeutics, Inc. (0001444192) (Issuer)
4 - Grace Therapeutics, Inc. (0001444192) (Issuer)
4 - Grace Therapeutics, Inc. (0001444192) (Issuer)
8-K - Grace Therapeutics, Inc. (0001444192) (Filer)
10-Q - Grace Therapeutics, Inc. (0001444192) (Filer)
SCHEDULE 13G/A - Grace Therapeutics, Inc. (0001444192) (Subject)
8-K - Grace Therapeutics, Inc. (0001444192) (Filer)
10-Q/A - Grace Therapeutics, Inc. (0001444192) (Filer)
8-K - Grace Therapeutics, Inc. (0001444192) (Filer)
10-Q - Grace Therapeutics, Inc. (0001444192) (Filer)
8-K - Grace Therapeutics, Inc. (0001444192) (Filer)
8-K - Grace Therapeutics, Inc. (0001444192) (Filer)
8-K - Grace Therapeutics, Inc. (0001444192) (Filer)
Fastest customizable press release news feed in the world
PRINCETON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that Chief Executive Officer Prashant Kohli will participate and present in TD Cowen's 46th Annual Health Care Conference, to be held March 2-4, 2026 in Boston, MA. Mr. Kohli's presentation is schedule for March 4, 2026 at 10:30 AM Eastern Time. To register for the webcast, click here. An archived replay will
FDA Established April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Phase 3 STRIVE-ON Safety Trial Data Presented at 2025 Society of Vascular and Interventional Neurology Annual Meeting Company Continues Pre-Commercial Planning in Anticipation of Potential FDA Approval of NDA Submission for GTx-104 for the Treatment of Patients with aSAH PRINCETON, N.J., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine b
PRINCETON, N.J., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that Chief Executive Officer Prashant Kohli will participate/present in the upcoming Craig-Hallum 16th Annual Alpha Select Conference, to be held Tuesday, November 18, 2025 in New York, NY. Companies attending the Alpha Select Conference have been individually selected by the Craig-Hallum research team and are
Announced U.S. Food and Drug Administration (FDA) Acceptance for Reviewof New Drug Application (NDA) for GTx-104 FDA Established April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Phase 3 STRIVE-ON Safety Trial Data Presented at 2025 Neurocritical Care Annual Meeting Granted Sixth U.S. Patent Covering IV Dosing Regimen for GTx-104 PRINCETON, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being
PRINCETON, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that an abstract of the Company's Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH (the STRIVE-ON trial–NCT05995405) has been accepted for presentation as a late breaking trial at the Society of Vascular and Interventional Neurology (SVIN) annual meeting, to be held November 19-22, 2025 in Orlando, FL.
PRINCETON, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for I.V. infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced it has secured approximately $4.0 million in additional funding through exercises of common warrants that were previously issued in a private placement that the Company closed in September 2023. The Company issued 1,345,464 new shares of common stock at an exercise price of $3.003 per share. The remaining 1,1
PRINCETON, N.J., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for I.V. infusion to address significant unmet medical needs in aSAH patients, today announced that results from its Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH (the STRIVE-ON trial–NCT05995405) were presented at the 2025 Neurocritical Care Society annual meeting, held in Montreal, Quebec, Canada September 18-21, 2025. In an oral presentation titled Safety and Tolerability of GTx-104 (Nimodipine Injection for I.V. Infusion
Grant of First Method of Use Patent Adds New Pillar to Grace's Multi-layered Intellectual Property and Potential Market Exclusivity Protection Patent Coverage Extended to 2043 PRINCETON, N.J., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for I.V. infusion to address significant unmet medical needs in aSAH patients, today announced that the U.S. Patent and Trademark Office has issued a U.S. Patent No. 12,414,943, titled "Nimodipine Parenteral Administration". The new method of use patent, publ
PRINCETON, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced that it will be featured as a presenting company at the H.C. Wainwright 27th Annual Global Investment Conference, being held virtually and in person September 8–10, 2025. The event will take place at the Lotte New York Palace Hotel in New York City. Virtual participation will be staged simultaneously, with more than 550 company presentations sch
FDA Establishes April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Comprehensive Data Package Supported by Positive Results from Phase 3 STRIVE-ON Safety Trial of GTx-104 PRINCETON, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced that on August 22, 2025 the U.S. Food and Drug Administratio
Live Leadership Updates
BEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugeboren to its Board of Directors as independent members, effective March 11, 2025 (the "Effective Date"). In addition, Matthew Wikler, M.D., and Natasha Giordano stepped down from the Board on the Effective Date. "We are thrilled to announce the addition of Keith and Edward to our Board," stated Jerome D. Jabbour, Chief Executive Officer of Matinas. "Their deep industry experience, leadership expertise, and capital markets acumen will be of great value as we move the company forward into a new era continu
This live feed shows all institutional transactions in real time.
SC 13G/A - Grace Therapeutics, Inc. (0001444192) (Subject)
SC 13G/A - Grace Therapeutics, Inc. (0001444192) (Subject)